MedImmune Turns To Venture Philanthropy For Cancer ImmunoRx Combination Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MedImmune and two non-profit research organizations are collaborating on clinical trials that explore the tricky world of combinations of novel cancer immunotherapies, including three MedImmune compounds in different stages of development.
You may also be interested in...
MedImmune Pipeline Primed To Produce
MedImmune, the biologics arm of performance-challenged AstraZeneca, is poised to lead the parent company into more prosperous times, with positive signals coming from Phase II trials in oncology and asthma and a stake in cancer immunotherapies.
Oncologists Audition Yervoy And Zelboraf For First-line Roles, With New Combos In Near Sight
Cooperative group plans trial testing Yervoy vs. Zelboraf in first-line metastatic melanoma to help settle the issue of which therapy should come first in BRAF-mutation positive patients. New therapies on the way promise to further complicate decision-making.
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?